• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Blood purification >Uremic Toxins and their Relation to Dialysis Efficacy
【24h】

Uremic Toxins and their Relation to Dialysis Efficacy

机译：尿毒毒素及其与透析效能的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Toxin retention is felt to be a major contributor to the development of uremia in patients with advanced chronic kidney disease and end-stage renal disease (ESRD). Uremic retention compounds are classically divided into 3 categories: small solutes, middle molecules, and protein-bound toxins. Compounds comprising the first category, for which the upper molecular weight limit is generally considered to be 500 Da, possess a high degree of water solubility and minimal or absent protein binding. The second category of middle molecules has largely evolved now to be synonymous with peptides and proteins that accumulate in uremia. Although not precisely defined, low-molecular weight proteins as a class have a molecular weight spectrum ranging from approximately 500 to 60,000 daltons. The final category of uremic retention compounds is protein-bound uremic toxins (PBUTs). As opposed to the above small, highly water-soluble toxins, which are largely by-products of protein metabolism, PBUTs have diverse origins and possess chemical characteristics that preclude the possibility of circulation in an unbound form despite being of low molecular weight. This review is the first in a series of papers designed to provide the current state of the art for extracorporeal treatment of ESRD. Subsequent papers in this series will address membranes, mass transfer mechanisms, and future directions. For small solutes and middle molecules, particular emphasis is placed on the important clinical trials that comprise the evidence base regarding the influence of dialytic solute removal on outcome. Because such trials do not exist for PBUTs, the discussion here is instead focused on solute characteristics and renal elimination mechanisms.
机译：感受到毒素保留是提高慢性肾病和终末期肾病（ESRD）尿毒症发展的主要因素。尿血症保留化合物经典分为3个类别：小溶质，中分子和蛋白质结合的毒素。包含第一类的化合物，其上部分子量限制通常被认为是500da，具有高度的水溶性和最小或不存在的蛋白质结合。第二类中间分子在很大程度上已经发展成为肽和蛋白质中积聚在尿毒症中的同义。虽然未精确定义，但作为阶级的低分子量蛋白质的分子量谱程范围为约500-60,000道尔顿。最终类别的尿毒剂保留化合物是蛋白质结合的尿毒毒素（PBUT）。与上述小的高度水溶性毒素相反，这是蛋白质代谢的主要产物，PButs具有多种的起源，并且尽管分子量低，但仍然能够以未结合的形式循环的可能性。这篇评论是一系列论文中的第一个，旨在为ESRD的体外治疗提供现有技术的现有技术。本系列的后续文件将解决膜，传质机制和未来方向。对于小溶质和中间分子，特别强调对重要的临床试验，其包括关于透析溶质去除对结果的影响的证据基础。因为这种试验不存在PBUT，所以这里的讨论集中在溶质特征和肾脏消除机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号